Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D J Flavell

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
British Journal of Cancer|January 1, 1997
Comparison of the potency and therapeutic efficacy of the anti-CD7 immunotoxin HB2-saporin constructed with one or two saporin moieties per immunotoxin moleculeD J Flavell, D A Boehm, A Noss, et al.
British Journal of Cancer|December 6, 2000
Anti-CD7 antibody and immunotoxin treatment of human CD7(+)T-cell leukaemia is significantly less effective in NOD/LtSz-scid mice than in CB.17 scid miceD J Flavell, S L Warnes, A L Noss, et al.
British Journal of Cancer|April 1, 1992
Effectiveness of combinations of bispecific antibodies for delivering saporin to human acute T-cell lymphoblastic leukaemia cell lines via CD7 and CD38 as cellular target moleculesD J Flavell, S Cooper, B Morland, et al.
Hematological Oncology|July 1, 1995
Comparison of the performance of anti-CD7 and anti-CD38 bispecific antibodies and immunotoxins for the delivery of saporin to a human T-cell acute lymphoblastic leukemia cell lineD J Flavell, S Cooper, K Okayama, et al.
Cancer Research|November 14, 1997
Systemic therapy with 3BIT, a triple combination cocktail of anti-CD19, -CD22, and -CD38-saporin immunotoxins, is curative of human B-cell lymphoma in severe combined immunodeficient miceD J Flavell, A Noss, K A Pulford, et al.
International Journal of Cancer|August 1, 1994
Therapy of human T-cell acute lymphoblastic leukaemia in severe combined immunodeficient mice with two different anti-CD7-saporin immunotoxins containing hindered or non-hindered disulphide cross-linkersD J Flavell, D A Boehm, K Okayama, et al.
Cell Biophysics|January 1, 1994
Immunotoxin studies in a model of human T-cell acute lymphoblastic leukemia developed in severe combined immune-deficient miceB J Morland, D Boehm, S U Flavell, et al.
British Journal of Cancer|February 24, 2001
Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxinD J Flavell, D A Boehm, A Noss, et al.
International Journal of Cancer|July 28, 1995
Therapy of human B-cell lymphoma bearing SCID mice is more effective with anti-CD19- and anti-CD38-saporin immunotoxins used in combination than with either immunotoxin used aloneD J Flavell, D A Boehm, L Emery, et al.
Clinical & Experimental Metastasis|November 1, 1994
Glycosylation patterns of the human colon cancer cell line HT-29 detected by Helix pomatia agglutinin and other lectins in culture, in primary tumours and in metastases in SCID miceU Schumacher, E Adam, D J Flavell, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
British Journal of Cancer|January 1, 1997
Comparison of the potency and therapeutic efficacy of the anti-CD7 immunotoxin HB2-saporin constructed with one or two saporin moieties per immunotoxin moleculeD J Flavell, D A Boehm, A Noss, et al.
British Journal of Cancer|December 6, 2000
Anti-CD7 antibody and immunotoxin treatment of human CD7(+)T-cell leukaemia is significantly less effective in NOD/LtSz-scid mice than in CB.17 scid miceD J Flavell, S L Warnes, A L Noss, et al.
British Journal of Cancer|April 1, 1992
Effectiveness of combinations of bispecific antibodies for delivering saporin to human acute T-cell lymphoblastic leukaemia cell lines via CD7 and CD38 as cellular target moleculesD J Flavell, S Cooper, B Morland, et al.
Hematological Oncology|July 1, 1995
Comparison of the performance of anti-CD7 and anti-CD38 bispecific antibodies and immunotoxins for the delivery of saporin to a human T-cell acute lymphoblastic leukemia cell lineD J Flavell, S Cooper, K Okayama, et al.
Cancer Research|November 14, 1997
Systemic therapy with 3BIT, a triple combination cocktail of anti-CD19, -CD22, and -CD38-saporin immunotoxins, is curative of human B-cell lymphoma in severe combined immunodeficient miceD J Flavell, A Noss, K A Pulford, et al.
International Journal of Cancer|August 1, 1994
Therapy of human T-cell acute lymphoblastic leukaemia in severe combined immunodeficient mice with two different anti-CD7-saporin immunotoxins containing hindered or non-hindered disulphide cross-linkersD J Flavell, D A Boehm, K Okayama, et al.
Cell Biophysics|January 1, 1994
Immunotoxin studies in a model of human T-cell acute lymphoblastic leukemia developed in severe combined immune-deficient miceB J Morland, D Boehm, S U Flavell, et al.
British Journal of Cancer|February 24, 2001
Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxinD J Flavell, D A Boehm, A Noss, et al.
International Journal of Cancer|July 28, 1995
Therapy of human B-cell lymphoma bearing SCID mice is more effective with anti-CD19- and anti-CD38-saporin immunotoxins used in combination than with either immunotoxin used aloneD J Flavell, D A Boehm, L Emery, et al.
Clinical & Experimental Metastasis|November 1, 1994
Glycosylation patterns of the human colon cancer cell line HT-29 detected by Helix pomatia agglutinin and other lectins in culture, in primary tumours and in metastases in SCID miceU Schumacher, E Adam, D J Flavell, et al.
Pageof 4